22 research outputs found
The reproducibility within the laboratory of findings in a three month toxicity study in the rat
A three month rat toxicity study was conducted twice with the same compound in the same laboratory. The studies were conducted according to internationally recognized guidelines for subchronic toxicity studies and followed essentially identical protocols (a control group and three dose groups, 10 rats/sex/ group). The compound was administered subcutaneously once daily for three months. Body weight and food and water intake were measured once weekly. Blood samples for hematology and blood chemistry were taken during the week before termination of dosing. Body weight gain and food and water intake were increased in both studies. For great many hematological and blood chemical parameters there was a dosedependent statistically significant increase or decrease in one or both sexes. Some changes attained only the level of significance in one study whereas there was a tendency of a similar change in the other study. Only a few deviations (no or opposit change in one study) were seen between the two studies. Altogether there seemed to be a good correspondance between the findings in the two studies and the variations seen would probably not influence the safety evaluation made from any of the studies
Das Einheitskonzept der »Konziliaren Gemeinschaft« in der ökumenischen Bewegung im Lichte der reformatorischen Theologie. Referat bei der Interkonfessionellen Theologischen Konferenz 1976 in Hermannstadt
Artificial Intelligence-Based Quantification of Epithelial Proliferation in Mammary Glands of Rats and Oviducts of Göttingen Minipigs
Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries.
To access publisher's full text version of this article click on the hyperlink belowLarge-scale observational cohorts may be used to study the effectiveness and rare side effects of biological disease-modifying anti-rheumatic drugs (bDMARDs) in ankylosing spondylitis (AS), but may be hampered by differences in baseline characteristics and disease activity across countries. We aimed to explore the research infrastructure in the five Nordic countries regarding bDMARD treatment in AS. This observational cohort study was based on data from biological registries in Denmark (DANBIO), Sweden (SRQ/ARTIS), Finland (ROB-FIN), Norway (NOR-DMARD), and Iceland (ICEBIO). Data were collected for the years 2010-2016. Registry coverage, registry inventory (patient characteristics, disease activity measures), and national guidelines for bDMARD prescription in AS were described per country. Incident (first line) and prevalent bDMARD use per capita, country, and year were calculated. In AS patients who started first line bDMARDs during 2010-2016 (n = 4392), baseline characteristics and disease activity measures were retrieved. Registry coverage of bDMARD-treated patients ranged from 60% to 95%. All registries included extensive prospectively collected data at patient level. Guidelines regarding choice of first line drug and prescription patterns varied across countries. During the period 2010-2016 prevalent bDMARD use increased (p < 0.001), whereas incident use tended to decrease (p for trend < 0.004), with large national variations (e.g. 2016 incidence: Iceland 10.7/100 000, Finland 1.7/100 000). Baseline characteristics were similar regarding C-reactive protein, but differed for other variables, including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (range 3.5-6.3) and Ankylosing Spondylitis Disease Activity Score (ASDAS) (2.7-3.8) (both p < 0.0001). Collaboration across the five Nordic biological registries regarding bDMARD use in AS is feasible but national differences in coverage, prescription patterns, and patient characteristics must be taken into account depending on the scientific question